Table 1.
Characteristics of patients (n = 95) in total and by prophylaxis group
| Characteristics | Total (n = 95) No. (%) | L-AMB, (n = 34) No. (%) | Posaconazole (n = 37) No. (%) | Micafungin (n = 24) No. (%) |
|---|---|---|---|---|
| Median age at diagnosis (years) | 6 | 4.5 | 6 | 6 |
| Sex | ||||
| Male | 50 (52.6) | 19 (55.9) | 18 (48.6) | 13 (54.2) |
| Female | 45 (47.4) | 15 (44.1) | 19 (51.4) | 11 (45.8) |
| Diagnosis | ||||
| ALL | 70 (73.7) | 25 (73,5) | 22 (59.5) | 23 (95.8) |
| HR-ALL | 34 (35.8) | 14 (41.2) | 14 (37.8) | 6 (25.0) |
| LR-/IR-ALL | 36 (37.9) | 11 (32.4) | 8 (21.6) | 17 (70.8) |
| AML | 25 (26.3) | 9 (26.5) | 15 (40.5) | 1 (4.2) |
| HR-AML | 22 (23.2) | 9 (26.5) | 12 (32.4) | 1 (4.2) |
| LR-/IR-AML | 3 (3.2) | 0 (0.0) | 3 (8.1) | 0 (0.0) |
| Relapse | 24 (25.3) | 12 (35.3) | 11 (29.7) | 1 (4.2) |
| ALL | 15 (15.8) | 9 (26.5) | 5 (13.5) | 1 (4.2) |
| AML | 9 (9.5) | 3 (8.8) | 6 (16.2) | 0 (0.0) |
| HSCT | 48 (50.5) | 21 (62.8) | 24 (64.9) | 3 (12.5) |
| ALL | 29 (30.5) | 14 (41.2) | 12 (32.4) | 3 (12.5) |
| AML | 19 (20) | 7 (20.6) | 12 (32.4) | 0 (0.0) |
| IFD | 14 (14.7) | 10 (29.4) | 4 (10.8) | 0 (0.0) |
| Death | 9 (9.5) | 7 (20.6) | 2 (5.4) | 0 (0.0) |
ALL acute lymphoblastic leukemia, AML acute myeloid leukemia, HSCT hematopoietic stem cell transplantation, IFD invasive fungal disease, L-AMB liposomal amphotericin B, No. Number